anti-inflammatory therapies for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
PRINCIPLE (COLCHICINE) ISRCTN86534580		RCT	colchicine	standard of care	COVID 19 outpatients	some concern	212/2081	inconclusive	inconclusive 29 % increase in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias inconclusive 8 % decrease in recovery (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis